Trial of new atherosclerosis vaccine gives promising results
10 May 2010
Researchers at the Swedish Karolinska Institutet have shown that inflammation of blood vessels that leads to atherosclerosis is caused by the immune defence's T cells attacking the "bad" LDL cholesterol accumulating in the walls of blood vessels.
By producing a vaccine against the T cell receptors, the researchers have managed to inhibit the development of atherosclerosis in animals. The study has been published in the Journal of Experimental Medicine and is expected to be of considerable significance to the future treatment of atherosclerosis, heart attack and stroke.
Cholesterol is transported in the blood in LDL particles, which are a kind of fat drops that can accumulate in the walls of blood vessels. LDL activates the immune defence and triggers an inflammation in the blood vessels that leads to atherosclerosis (also known as arteriosclerosis). When the atherosclerotic plaque finally ruptures, a blood clot is formed that in turn can cause a heart attack or stroke.
It was previously thought that the inflammation in the blood vessels arises when the T cells react to oxidised LDL particles located in the atherosclerotic plaque. Now, however, the team at Karolinska Institutet has found that the opposite is true, namely that the T cells react to components in the normal LDL particles, and that they no longer recognise LDL once it has been oxidised.
"Since reactions to LDL can be dangerous, T cells are normally held in check by inhibitory signals," says Professor Göran K Hansson, professor of experimental cardiovascular science at the Department of Medicine, who led the study. "The body's own control works well as long as the LDL keeps to the blood, liver and lymph glands. But when it accumulates in the artery wall, this inhibition is no longer enough, the T cells are activated and an inflammation arises."
Together with his research group at Karolinska Institutet he now presents a new principle for inhibiting atherosclerosis. Vaccination against the receptor that the T cells use to recognise LDL can block the immune reaction and reduce the disease by between 60 and 70%. The vaccine has been successfully tested on animals and the researchers are now hoping to see if it can be developed into a treatment for patients with a high risk of myocardial infarction and stroke.
The researchers also now believe that their results explain why antioxidants are ineffective against cardiovascular disease when they have been tested in large clinical studies.
"If one takes antioxidants, one simply prevents the oxidation of LDL," says Professor Hansson. "It retains its ability to activate the T cells, and so the inflammation in the blood vessels can increase. This could give the opposite results to what one was hoping for."